It has no current market, not even a prescription price. Its makers stopped commercial production years ago, because demand was so low. But an antibiotic long abandoned as a weak, low-dose treatment for tuberculosis may have found renewed purpose, this time as a potent, high-dose fighter against the most common and actively contagious form of the lung disease.
Post new comment